NovaBridge Board Moves to Oust Director Xin Liu at September AGM
NBP sits 26% above its 52-week low of $1.46 on light trading volume (0.2× avg).
Summary
NovaBridge Biosciences' board has proposed removing director Xin Liu at the upcoming annual general meeting, recommending shareholders vote in favor. The move follows a recent CEO overhaul and suggests continued board-level restructuring.
Key Events · Executive and Board Changes · NBP
-
Director Removal Proposed
The board proposes removing Ms. Xin Liu as a director effective immediately upon shareholder approval at the September 8, 2026 AGM.
-
Board Recommends FOR Vote
Citing efforts to enhance governance and optimize board composition, the board states the removal is in the best interests of the company and shareholders.
-
Governance Overhaul Continues
This follows the appointment of a new CEO on June 29, 2026, and adoption of a new incentive plan on July 17, 2026, indicating a broader leadership and governance restructuring.
-
Shareholder Vote Deadline
ADS holders must submit voting instructions by September 1, 2026; ordinary shareholders by September 6, 2026.
Analysis · NBP · Life Sciences
Shareholders are being asked to vote out director Xin Liu at the annual meeting on September 8, 2026. While the filing frames this as an effort to optimize board size and improve governance, a board-initiated removal of a sitting director is unusual and signals internal disagreement or a strategic pivot. Coming just weeks after a CEO change and a new incentive plan, it adds to a picture of significant leadership turnover.
At the time of this filing, NBP was trading at $1.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $204.2M. The 52-week trading range was $1.46 to $6.79. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.